01—Abstract
Summary
Summary of the 8-K filed October 15, 2024. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (EXEL) reported in this Form 8-K, filed October 15, 2024, under Item 8.01 (Other Events), that on October 14, 2024 it entered into a clinical development collaboration with Merck & Co., Inc., known as MSD outside of the United States and Canada.
The collaboration covers Exelixis' investigational tyrosine kinase inhibitor zanzalintinib combined with Merck's KEYTRUDA (pembrolizumab) in a phase 3 pivotal trial for head and neck squamous cell carcinoma (HNSCC), and zanzalintinib combined with WELIREG (belzutifan), Merck's oral HIF-2α inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for renal cell carcinoma (RCC). Under the terms, Merck will supply KEYTRUDA for the ongoing, Exelixis-sponsored phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC. Merck will sponsor the phase 1/2 trial and two phase 3 pivotal RCC trials, fund one of the phase 3 studies, and Exelixis will co-fund the phase 1/2 trial and the other phase 3 study while also supplying zanzalintinib and cabozantinib.
Exelixis retains all global commercial and marketing rights to zanzalintinib. The filing is a notice of a clinical development collaboration and includes standard forward-looking statement cautions. It does not state financial terms of the collaboration, such as payments or cost amounts.
02—Key points
Key Highlights
- Exelixis announced on October 14, 2024 a clinical development collaboration with Merck & Co., Inc. (MSD outside the U.S. and Canada).
- Zanzalintinib, Exelixis' investigational TKI, will be evaluated with KEYTRUDA in a phase 3 pivotal trial in HNSCC.
- Merck will supply KEYTRUDA for the ongoing Exelixis-sponsored phase 3 STELLAR-305 trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC.
- Zanzalintinib will be combined with WELIREG (belzutifan) in a phase 1/2 trial and two phase 3 pivotal trials in renal cell carcinoma (RCC).
- Merck will sponsor the RCC phase 1/2 trial and two phase 3 pivotal trials, and fund one of the phase 3 studies.
- Exelixis will co-fund the phase 1/2 RCC trial and the other phase 3 study, and supply zanzalintinib and cabozantinib.
- Exelixis maintains all global commercial and marketing rights to zanzalintinib.
03—Questions
Frequently Asked Questions
What is the collaboration between Exelixis and Merck?
Exelixis and Merck entered into a clinical development collaboration to evaluate zanzalintinib, Exelixis' investigational TKI, in combination with Merck's KEYTRUDA in HNSCC and with Merck's WELIREG in RCC, across phase 1/2 and phase 3 pivotal trials.
What are the respective roles of Exelixis and Merck?
Merck will supply KEYTRUDA for the STELLAR-305 trial, which Exelixis sponsors, and will sponsor a phase 1/2 trial and two phase 3 pivotal RCC trials, funding one of the phase 3 studies. Exelixis will co-fund the phase 1/2 trial and the other phase 3 study and supply zanzalintinib and cabozantinib.
Does Exelixis keep commercial rights to zanzalintinib?
Yes. The filing states that Exelixis maintains all global commercial and marketing rights to zanzalintinib.
Does the filing disclose the financial terms of the collaboration?
The filing describes the division of trial sponsorship, funding and supply responsibilities but does not state payment amounts or other financial terms of the collaboration.
04—Continue